BTIG raised the firm’s price target on Liquidia (LQDA) to $37 from $29 and keeps a Buy rating on the shares after the company announced that the FDA has approved Yutrepia inhalation powder for adults with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease and set an annualized WAC price for Yutrepia of $317,000, which the firm notes is in line with Tyvaso DPI. In the near term, the firm expects most investor focus on the pending temporary restraining order request filed by United Therapeutics (UTHR) in the ‘782 lawsuit, but the firm adds that it sees “low odds” of Liquidia being enjoined by United now with full FDA approval of Yutrepia confirmed.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LQDA:
- Liquidia price target raised to $31 from $27 at Jefferies
- Liquidia Technologies: Overcoming Legal Hurdles with Yutrepia’s FDA Approval and Positive Growth Outlook
- Liquidia price target raised to $25 from $22 at BofA
- Buy Rating for Liquidia Technologies: Strategic Positioning and Market Potential Drive Optimism
- Liquidia Technologies Gains FDA Approval for YUTREPIA
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue